We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.
We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising. Our clients include Novartis, Pfizer, Bayer, Merck, GSK, and Johnson & Johnson among many others.
News & insights
Blog Post: 13 AUGUST 2021
The European Commission has announced that the Clinical Trials Regulation, already enacted in 2014, will take effect on 31 January 2022.Read more
Blog Post: 20 JULY 2021
The UK Competition and Markets Authority (CMA) has imposed over GBP260 million in fines on several drug makers for two breaches of competition law: (i) charging excessive and unfair prices, in breach…Read more
Blog Post: 14 JULY 2021
Last week, the UK Government (the Government) released its ‘Life Sciences Vision’ (the LSV), which sets out the Government and the life science sector’s ambitions for the next 10 years.Read more
Publications: 09 JUNE 2021
On Tuesday 25 May 2021, Allen & Overy IP associate Tine Carmeliet chaired a presentation with IP partner Keren Livneh and IP associate Megan McMellon and M&A associate Zara Sproul on “Drug…Read more